2026-02-02 02:42Summary of CSPC Pharma (1093.HK) Conference Call Company Overview - Company: CSPC Pharma - Ticker: 1093.HK - Industry: Pharmaceuticals Key Points from the Conference Call Landmark Deal with AstraZeneca - CSPC signed a significant licensing agreement with AstraZeneca (AZN) for the development of long-acting peptide medicine using sustained-release delivery technology and AI-driven peptide drug discovery platform - CSPC will license out the ex-China rights of eight assets, including: - A once-monthly injectable weight management portfolio consisting of SYH2082 (GLP-1/GIP, progressing into phase 1) - Three pre-clinical assets with different mechanisms - Four additional new programs - CSPC will receive an upfront payment of US$1.2 billion and potential R&D/sales milestone payments of up to US$17.3 billion, plus double-digit royalties on net sales - This marks CSPC's third collaboration with AZN, following previous licensing deals for an Lp(a) inhibitor and AI technology collaboration [1][2] Stock Price Reaction - Following the deal announcement, CSPC's share price closed down by -10.2% on January 30, 2026 - Investor sentiment towards the deal was generally positive, citing: - AstraZeneca's focus on cardio-metabolism and sourcing differentiated assets from China - Record-breaking deal size for China-to-West therapeutic agreements - The decline in share price was attributed to high expectations built into the stock price prior to the announcement, with CSPC's share price having increased by +43% since December 16, 2025 [2] Long-Acting GLP-1 Class Differentiation - The competition in the GLP-1 class is intensifying, and potential differentiation for latecomers may arise from: - More convenient long-acting dosage forms - Indication differentiation with additional clinical benefits beyond weight loss - Commercial synergy from a comprehensive product portfolio - Leading players in the long-acting GLP-1 agonist space include maridebart cafraglutide (Amgen, in phase 3) and MET-097 (Pfizer, in phase 3) [3][7] Earnings Estimates and Valuation Changes - Earnings estimates for 2026E and 2027E have been revised upwards by +85.5% and +5.3%, respectively, to account for the upfront payment and potential higher collaboration income - The 12-month price target has been raised to HK$11.87 from HK$10.57, based on a sum-of-the-parts (SOTP) valuation: - DCF-based valuation of HK$6.7 billion for NBP - HK$77.7 billion for new product wave with global value added for oral GLP-1 - HK$36.3 billion for legacy portfolio and generics business - API business valued at HK$3.9 billion based on a 4.7x 2026E P/E - The discount rate used for valuation is 9% [8][9] Risks and Considerations - Key downside risks include: - Earlier-than-expected value-based pricing (VBP) for NBP - Slower-than-expected ramp-up of new products - Failure of major R&D projects - Greater-than-expected price cuts impacting generic drug sales - CSPC maintains a "Buy" rating despite these risks [9][10] Market Context - CSPC's market capitalization is approximately HK$110.6 billion (US$14.2 billion) - The company is positioned within the China Pharma & Biotech sector, with a notable M&A rank of 3 [10]